Aktis Oncology Conference Call Summary Company Overview - **Company**: Aktis Oncology - **Focus**: Targeted radiopharmaceuticals aimed at transforming anti-cancer medicines, particularly for patients lacking existing radiopharmaceutical options [3][4] Core Industry Insights - **Radiopharmaceuticals**: The industry is at an inflection point similar to antibody-drug conjugates (ADCs) five years ago, with significant opportunities for new products [4] - **Target Space**: The current market has limited approved medicines, presenting a "white space opportunity" for new entrants [4] Key Programs and Targets - **Lead Program 1189 (Nectin-4)**: - **Target**: Nectin-4, expressed in various cancers including bladder, breast, lung, cervical, head and neck, and colorectal cancers [18] - **Clinical Validation**: Supported by existing data from PADCEV, a validated treatment for bladder cancer [19] - **Patient Impact**: Aims to provide a radiopharmaceutical option for large patient populations currently without one [18][19] - **Second Program 2519 (B7-H3)**: - **Target**: B7-H3, expressed in lung and prostate cancers, among others [36] - **Competitive Landscape**: While there are existing ADCs targeting B7-H3, Aktis aims to differentiate with a unique isotope (Actinium-225) and a non-overlapping toxicity profile [36][37] Clinical Development and Data - **Imaging Data**: Initial human imaging data for both programs showed high tumor uptake and favorable dosimetry profiles, suggesting a strong therapeutic index [27][29] - **Phase 1b Studies**: Ongoing dose escalation studies for both programs, with updates expected throughout the year [32][38] Supply Chain and Manufacturing - **End-to-End Supply Chain**: Aktis has developed its own supply chain capabilities, including a GMP manufacturing facility expected to open by the end of the year [10][11] - **Actinium Supply**: Multiple supply deals in place to ensure a robust supply of Actinium-225 [15] Partnerships and Collaborations - **Collaboration with Eli Lilly**: Focused on discovery capabilities for novel miniprotein radioconjugates, with successful milestone achievements ahead of schedule [12][13] - **Business Development Strategy**: Emphasis on retaining economic rights to lead programs while exploring partnerships that enhance shareholder value [46] Financial Position - **IPO Proceeds**: Raised $340 million in net proceeds from the IPO, with a cash runway projected into 2029, supporting ongoing clinical development [49][50] Conclusion - **Strategic Positioning**: Aktis Oncology is well-positioned in the radiopharmaceutical space with a strong pipeline, innovative technology, and a solid financial foundation, aiming to address significant unmet needs in cancer treatment [16][50]

Summary of Telix Pharmaceuticals FY Conference Call Company Overview - **Company Name**: Telix Pharmaceuticals (NasdaqGS:TLX) - **Industry**: Targeted Radiopharmaceuticals - **Revenue**: Expected to be just under $1 billion for the year, primarily from precision medicine, specifically imaging [3][6] - **Global Presence**: Commercially active in 26 countries with a diverse R&D pipeline focused on therapeutic oncology [3][4] - **R&D Investment**: Approximately $300 million allocated for R&D and infrastructure development [3] Key Products Precision Medicine - **Illuccix**: - Flagship product launched in 2021, a PSMA-targeting agent. - Competes with Lantheus, which had a first-mover advantage. - Transitioned off transitional pass-through reimbursement in Q2 last year [9][10]. - **Gozellix**: - Lifecycle management product for Illuccix, with reimbursement secured. - Offers clinical advantages, including a longer shelf life and improved transport capabilities [10][11]. - Aims to service high-volume accounts and penetrate underserved areas [11][12]. Therapeutics - **TLX591**: - Antibody linked to lutetium-177, currently in a pivotal study for prostate cancer. - The study has transitioned to the randomized phase, with data expected soon [28][30]. - **Zircaix**: - Focused on renal cell carcinoma, with a BLA filed and expected to launch this year. - The company is harmonizing EU and US submissions to streamline the approval process [23][25][27]. Market Dynamics - **Prostate Imaging Market**: - Estimated growth of 5%-7% annually, driven by increasing awareness and clinical value of PSMA imaging [16]. - BiPASS trial aims to potentially double the market size by adding 800,000 scans [18][19]. - **PET Scanner Capacity**: - Increasing demand for PET scans due to growth in various disease areas. - New installations and advancements in scanner technology are expected to alleviate capacity issues [20][21]. Regulatory Challenges - **FDA Interactions**: - Experienced setbacks with two CRLs for glio and renal products, but ongoing collaboration with the FDA is noted as positive [24][26]. - Learning curve in submitting PET biologics, with expectations for approval still high [27]. Competitive Landscape - **Market Positioning**: - Aims to differentiate from competitors like Pluvicto by focusing on survival benefits and unique dosing regimens [47][49]. - Emphasizes the importance of OS (Overall Survival) as a key metric for success in the market [50][51]. Future Outlook - **Pipeline Development**: - Plans to expand therapeutic offerings with a focus on combination therapies, particularly in renal cancer [61]. - Anticipates significant data releases and product launches in 2026, with a strong emphasis on diagnostics and therapeutics [62]. Conclusion - Telix Pharmaceuticals is positioned as a significant player in the targeted radiopharmaceutical space, with a robust pipeline and strategic focus on both diagnostics and therapeutics. The company is navigating regulatory challenges while aiming for market differentiation through innovative product offerings and a strong emphasis on clinical outcomes.

Table of Contents As filed with the Securities and Exchange Commission on January 7, 2026. Registration No. 333-292283 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Copies to: Siavosh Salimi William A. Magioncalda Paul Hastings LLP The MetLife Building 200 Park Avenue New York, New York 10166 (212) 318-6000 Aktis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 85- ...

Table of Contents As filed with the Securities and Exchange Commission on January 5, 2026. Registration No. 333-292283 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aktis Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 85-2584233 (State or other jurisdiction of Incorporation or organization (Primary Standard Industrial Classification Code Number) (I.R.S. Employer ...

Table of Contents As filed with the Securities and Exchange Commission on December 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aktis Oncology, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of Incorporation or organization Delaware 2834 85-2584233 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 17 ...

Core Insights - Molecular Partners AG presented new data on MP0712, a Radio-DARPin targeting DLL3, at the Targeted Radiopharmaceuticals Summit Europe, showcasing promising human imaging results and supporting mechanism of action data [1][2][3] Clinical Development - MP0712 is being developed in collaboration with Orano Med for treating small cell lung cancer (SCLC) and other neuroendocrine cancers, with a Phase 1 trial expected to start by the end of 2025 [1][7] - The Phase 1 Investigational New Drug (IND) application has been filed, and ongoing discussions with the FDA are taking place [7][8] Imaging and Efficacy - Initial imaging results indicate targeted delivery of MP0712 into tumors with minimal exposure to healthy organs, suggesting its potential effectiveness in a clinical setting [2][3] - A case study showed specific uptake in tumor lesions at 24 hours, sustained over four days, with limited accumulation in healthy organs [3][5] Mechanism of Action - MP0712 is engineered for half-life optimization to maintain drug levels in the blood, supporting its intended mechanism of action [3][6] - The data suggests that MP0712 can achieve high tumor uptake even with low DLL3 expression levels, leveraging internalization and optimal binding properties [6] Future Outlook - The company anticipates initial clinical data from the Phase 1/2a study in 2026, which will assess safety and determine a recommended phase 2 dose for MP0712 [7][8] - Molecular Partners is also advancing additional Radio-DARPin programs in 2026 [2][8] Technology and Innovation - The Radio-DARPin platform combines the targeting capabilities of DARPins with the therapeutic potential of 212Pb, aiming to improve the delivery of radioactive payloads to solid tumors [11] - DARPins are designed to offer high specificity and affinity, making them suitable for efficient delivery of therapeutic radionuclides [12]